HYPOGONADOTROPIC HYPOGONADISM 21 WITH ANOSMIA, SUSCEPTIBILITY TO
|
phenotype |
|
Finding
|
2
|
3
|
0.100 |
None |
|
0 |
3
|
|
|
HYPOGONADOTROPIC HYPOGONADISM 21 WITH OR WITHOUT ANOSMIA
|
disease |
|
Disease or Syndrome
|
2
|
4
|
0.100 |
None |
|
0 |
4
|
|
|
Platelet mean volume determination (procedure)
|
phenotype |
|
Laboratory Procedure
|
223
|
371
|
0.100 |
None |
1.000 |
1 |
1
|
2009 |
2009 |
Drug Dependence
|
group |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
248
|
31
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Drug Use Disorders
|
group |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
121
|
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Drug habituation
|
phenotype |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
196
|
19
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Drug abuse
|
group |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
405
|
39
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Substance-Related Disorders
|
group |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
128
|
20
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Organic Mental Disorders, Substance-Induced
|
disease |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
115
|
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Prescription Drug Abuse
|
phenotype |
Chemically-Induced Disorders; Mental Disorders
|
Finding
|
115
|
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Substance Dependence
|
disease |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
156
|
19
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Substance Use Disorders
|
group |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
218
|
16
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Substance abuse problem
|
disease |
Chemically-Induced Disorders; Mental Disorders
|
Mental or Behavioral Dysfunction
|
185
|
20
|
0.300 |
None |
1.000 |
1 |
|
2010 |
2010 |
Hypertensive disease
|
group |
Cardiovascular Diseases
|
Disease or Syndrome
|
2322
|
1085
|
0.100 |
None |
1.000 |
1 |
2
|
2011 |
2011 |
Pervasive Development Disorder
|
group |
Mental Disorders
|
Mental or Behavioral Dysfunction
|
328
|
49
|
0.010 |
None |
1.000 |
1 |
1
|
2011 |
2011 |
Corneal Topography
|
phenotype |
|
Diagnostic Procedure
|
39
|
98
|
0.100 |
None |
1.000 |
1 |
1
|
2011 |
2011 |
Bipolar Disorder
|
disease |
Mental Disorders
|
Mental or Behavioral Dysfunction
|
1183
|
839
|
0.100 |
None |
1.000 |
1 |
1
|
2013 |
2013 |
Crohn Disease
|
disease |
Digestive System Diseases
|
Disease or Syndrome
|
1382
|
1147
|
0.010 |
None |
1.000 |
1 |
|
2013 |
2013 |
Colorectal Carcinoma
|
disease |
Digestive System Diseases; Neoplasms
|
Neoplastic Process
|
5473
|
1962
|
0.010 |
None |
1.000 |
1 |
|
2015 |
2015 |
Thyroid associated orbitopathy
|
disease |
|
Disease or Syndrome
|
7
|
4
|
0.010 |
None |
1.000 |
1 |
1
|
2016 |
2016 |
Malignant neoplasm of liver
|
disease |
Digestive System Diseases; Neoplasms
|
Neoplastic Process
|
1649
|
88
|
0.300 |
None |
1.000 |
1 |
|
2016 |
2016 |
Liver neoplasms
|
group |
Digestive System Diseases; Neoplasms
|
Neoplastic Process
|
1424
|
7
|
0.300 |
None |
1.000 |
1 |
|
2016 |
2016 |
Antiphospholipid antibodies measurement
|
phenotype |
|
Laboratory Procedure
|
6
|
8
|
0.100 |
None |
1.000 |
1 |
1
|
2016 |
2016 |
Epstein-Barr Virus Infections
|
group |
Infections
|
Disease or Syndrome
|
384
|
72
|
0.100 |
None |
1.000 |
1 |
1
|
2017 |
2017 |
HIV Infections
|
group |
Infections; Immune System Diseases
|
Disease or Syndrome
|
807
|
142
|
0.100 |
None |
1.000 |
1 |
1
|
2017 |
2017 |